Oncrasin-1类衍生物对来自肺癌、结肠癌等多种癌细胞系都具有高度活性,其中NSC-743380活性最佳。然而,它在结构上存在问题,易形成二聚体而失活,限制了进一步的研究发展。因此,本文以Oncrasin-1为先导化合物,设计了13种衍生物,通过引入...Oncrasin-1类衍生物对来自肺癌、结肠癌等多种癌细胞系都具有高度活性,其中NSC-743380活性最佳。然而,它在结构上存在问题,易形成二聚体而失活,限制了进一步的研究发展。因此,本文以Oncrasin-1为先导化合物,设计了13种衍生物,通过引入氨基和酰胺基,尝试提高化合物稳定性并保留活性。化合物结构经1 H NMR,13 C NMR,HR-MS(ESI)表征,并通过细胞增殖实验(CCK-8实验)测定其对人胰腺癌细胞(PANC-1)、人宫颈癌细胞(HeLa)和人肝癌细胞(HepG2)的抗肿瘤活性。结果表明,13个Oncrasin-1类衍生物中,有10个表现出更好的活性,其中化合物4((4-(((1-(4-氯苄基)-1 H-吲哚-3-基)甲基)氨基)丁基)氨基甲酸叔丁酯)对HeLa的IC 50达到了3.98μM。展开更多
A new compound 386 A, which is a derivative of tetrahydrofuranotetrahydropyran, was isolated from the culture of the marine fungus Penicillin sp (386). Its structure was elucidated with spectroscopic methods, mainly 2...A new compound 386 A, which is a derivative of tetrahydrofuranotetrahydropyran, was isolated from the culture of the marine fungus Penicillin sp (386). Its structure was elucidated with spectroscopic methods, mainly 2D NMR techniques.展开更多
文摘Oncrasin-1类衍生物对来自肺癌、结肠癌等多种癌细胞系都具有高度活性,其中NSC-743380活性最佳。然而,它在结构上存在问题,易形成二聚体而失活,限制了进一步的研究发展。因此,本文以Oncrasin-1为先导化合物,设计了13种衍生物,通过引入氨基和酰胺基,尝试提高化合物稳定性并保留活性。化合物结构经1 H NMR,13 C NMR,HR-MS(ESI)表征,并通过细胞增殖实验(CCK-8实验)测定其对人胰腺癌细胞(PANC-1)、人宫颈癌细胞(HeLa)和人肝癌细胞(HepG2)的抗肿瘤活性。结果表明,13个Oncrasin-1类衍生物中,有10个表现出更好的活性,其中化合物4((4-(((1-(4-氯苄基)-1 H-吲哚-3-基)甲基)氨基)丁基)氨基甲酸叔丁酯)对HeLa的IC 50达到了3.98μM。
文摘A new compound 386 A, which is a derivative of tetrahydrofuranotetrahydropyran, was isolated from the culture of the marine fungus Penicillin sp (386). Its structure was elucidated with spectroscopic methods, mainly 2D NMR techniques.